API | idarucizumab

idarucizumab (praxbind) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA First in Class Accelerated Approval ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
idarucizumab

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$2697.1600

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

adabi-fab | bi 655075 | bi-655075 | idarucizumab | praxbind

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (1)

Hemorrhage

Experimental Indications - Clinical Trial Phases 1-4 (2)

Healthy Volunteers (Phase 1)

Hemorrhage ()

Overview

Highest Phase: Phase 3
# of Trials: 8
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue